AbbVie to acquire Cerevel Therapeutics for $45/share (~$8.7B equity value)

AbbVie Inc.

Transaction valued at $45.00 per Cerevel share, total equity ~$8.7B; approved by both boards.
Cerevel's late-stage asset emraclidine is a potential best-in-class antipsychotic for schizophrenia.
Deal expected to close mid-2024, subject to Cerevel shareholder vote, regulatory approvals, and customary conditions.
Acquisition adds multiple clinical assets: tavapadon (Parkinson's), CVL-354 (MDD), darigabat (epilepsy/panic).
AbbVie expects transaction to be accretive to adjusted diluted EPS beginning in 2030.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.